134 related articles for article (PubMed ID: 23900743)
1. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.
Truong M; Cook MR; Pinchot SN; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2011 May; 18(5):1506-11. PubMed ID: 21184191
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Kunnimalaiyaan M; Ndiaye M; Chen H
Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
[TBL] [Abstract][Full Text] [Related]
4. Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.
Ning L; Jaskula-Sztul R; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2008 Sep; 15(9):2600-5. PubMed ID: 18563491
[TBL] [Abstract][Full Text] [Related]
5. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.
Ning L; Greenblatt DY; Kunnimalaiyaan M; Chen H
Oncologist; 2008 Feb; 13(2):98-104. PubMed ID: 18305053
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide suppresses growth in human medullary thyroid cancer cells.
Alhefdhi A; Burke JF; Redlich A; Kunnimalaiyaan M; Chen H
J Surg Res; 2013 Nov; 185(1):212-6. PubMed ID: 23816245
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
Somnay Y; Simon K; Harrison AD; Kunnimalaiyaan S; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2013 Jan; 24(1):66-72. PubMed ID: 23147412
[TBL] [Abstract][Full Text] [Related]
8. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.
Greenblatt DY; Cayo MA; Adler JT; Ning L; Haymart MR; Kunnimalaiyaan M; Chen H
Ann Surg; 2008 Jun; 247(6):1036-40. PubMed ID: 18520232
[TBL] [Abstract][Full Text] [Related]
11. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
Samadi AK; Bazzill J; Zhang X; Gallagher R; Zhang H; Gollapudi R; Kindscher K; Timmermann B; Cohen MS
Surgery; 2012 Dec; 152(6):1238-47. PubMed ID: 23158190
[TBL] [Abstract][Full Text] [Related]
12. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.
Koga K; Hattori Y; Komori M; Narishima R; Yamasaki M; Hakoshima M; Fukui T; Maitani Y
Cancer Sci; 2010 Apr; 101(4):941-7. PubMed ID: 20704575
[TBL] [Abstract][Full Text] [Related]
13. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
[TBL] [Abstract][Full Text] [Related]
14. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
15. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
17. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
18. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
19. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Pitt SC; Chen H; Kunnimalaiyaan M
Ann Surg Oncol; 2009 Oct; 16(10):2936-42. PubMed ID: 19588205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
